

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: Elastagen Pty Ltd

主要联系人姓名: Robert Daniels

主要联系人职务: 首席执行官

公司网址: www.elastagen.com

公司地址: Australian Technology Park, National Innovation Centre, 4 Cornwallis Street, Eveleigh, NSW 2015

公司未上市

公司简介

Elastagen 是一家医学公司，生产一系列以重组人类弹性蛋白原（弹性蛋白组成成分）为基底的先进产品。弹性蛋白是人体组织重要的物理性和生物性组成成分，包括皮肤、肺、动脉、弹性韧带皆由多种弹性蛋白原组成。Elastagen 通过其创办科学家 Weiss 教授和他领导的悉尼大学团队率先对弹性蛋白原进行了科学研究，开发多种生产和配制弹性蛋白原的方法，并申请了专利保护。Elastagen 是首家唯一提供全长、可扩展、符合现行药品生产管理规范（cGMP）临床级别的商用人类弹性蛋白原的供应商。Elastagen 相信弹性蛋白原凭借其独特的物理弹性特质和帮助组织修复的能力，可在医疗和美容许多应用层面上作出广泛贡献。

关键技术或领先技术

Elastagen 依托对弹性蛋白原生物特性的深入科学理解和针对特定应用进行重组蛋白定制的生产调配能力，正在广泛开发多款产品。

Elastagen 的主要研发产品有：

- 针对萎缩性疤痕（如妊娠纹）的非手术性治疗产品
- 帮助皮肤恢复青春活力的护肤产品
- 除疤手术和伤口修复用的真皮基质

Elastagen 同时正在开发弹性蛋白原以作为外科手术用密封剂，并已成功取得领域内的临床前概念验证。

类别

设备类:

美容医学

伤口护理

其他, 请注明: 恢复皮肤青春活力、去除妊娠纹、手术用粘合剂和密封剂

关键或领先技术的发展阶段

临床试验中阶段

合作机会

Elastagen 正在寻求第二轮融资以获取关键增值里程碑目标, 包括为非手术性妊娠纹治疗产品和护肤产品获取 CE 标志, 并完成除疤手术和伤口修复用真皮基质的临床概念验证。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: Elastagen Pty Ltd

Key contact name: Robert Daniels

Job title of key contact: Chief Executive Officer

Company website address: www.elastagen.com

Company address: Australian Technology Park, National Innovation Centre, 4 Cornwallis Street, Eveleigh, NSW 2015

The company is Unlisted.

ABOUT THE COMPANY

Elastagen is a medical company with an advanced pipeline of products based on recombinant human tropoelastin, the building block of elastin. Elastin is a critical physical and biological component of human tissues, such as the skin, lungs, arteries, and elastic ligaments, and is comprised of multiple copies of the protein tropoelastin. Elastagen, through its founding scientist Prof Weiss and his team at the University of Sydney, has pioneered the scientific understanding of tropoelastin and developed and patented a range of approaches to manufacture and formulate tropoelastin.

Elastagen is the first and only provider of full length, scalable, commercial cGMP clinical grade human tropoelastin. We believe tropoelastin has broad utility in a range of medical and aesthetic applications based on its unique physical elastic properties and its ability to support tissue repair.

KEY OR LEAD TECHNOLOGY

Elastagen is developing a broad portfolio of products built on its strong scientific understanding of tropoelastin biology and ability to manufacture and formulate the recombinant protein to tailor its properties to the relevant application.

Elastagen's main development products are:

- Non-surgical treatment of atrophic scars such as stretch marks
- Dermo-aesthetic product for the rejuvenation of skin
- Dermal matrix for the surgical revision of scars and wound repair

The Company is also developing tropoelastin as a surgical sealant and has achieved preclinical proof of concept in this area.

Category

Devices:

Aesthetics

Wound care

Skin rejuvenation; Stretch mark scar treatment; Surgical glues and sealants

Point of development of key or lead technology

In clinical trials

OPPORTUNITIES SOUGHT

Elastagen is seeking Series B funding to support the business through to key value adding milestones including the attainment of CE Mark for both the non-surgical treatment of stretch marks and the dermo-aesthetic product and completion of clinical proof of concept for our dermal matrix for the surgical revision of scars and wound repair.